New antibody combo tested in advanced cancer patients

NCT ID NCT05025085

Completed Disease control Sponsor: Agenus Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a new antibody drug called AGEN1777, given alone or with another antibody (a PD-1 inhibitor), in 25 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see how the drug moves through the body. Because it is a phase 1 study, it is too early to know if the drug works well.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AGEN1777 (an antibody) and a PD-1 inhibitor (another antibody)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early phase 1 trial with only 25 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects, and it is far from being proven effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER

Contacts and locations

Locations

Lifespan Cancer Institute

Providence, Rhode Island, 02903, United States
Local Institution - 0001

Providence, Rhode Island, 02903, United States
Local Institution - 024

Southfield, Michigan, 48075, United States
Local Institution - 072

Cincinnati, Ohio, 45267-0558, United States
Local Institution - 164

Dallas, Texas, 75230, United States
Local Institution - 165

Grand Rapids, Michigan, 49546, United States
MD Anderson Cancer Center Thoracic-Head & Neck Med Onc

Houston, Texas, 77030, United States
Mary Crowley Cancer Research

Dallas, Texas, 75251, United States
Providence Cancer Institute

Portland, Oregon, 97213, United States
START Midwest

Grand Rapids, Michigan, 49546, United States
University of Cincinnati Cancer Center

Cincinnati, Ohio, 45267, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.